Adalimumab-Receiving Ulcerative Colitis Patient Suffered Latent Tuberculosis Reactivation Despite Correct Chemoprophylaxis and was Successfully Treated while on Anti-Tumour Necrosis Factor Therapy.

Belén Agudo, Gema Díaz, Yago González-Lama

Journal of Crohn's & colitis 2016 May 23

filter terms:

all
biogroup
compound
phenotype
show more »
show less «

No abstract available.

Citation

Belén Agudo, Gema Díaz, Yago González-Lama. Adalimumab-Receiving Ulcerative Colitis Patient Suffered Latent Tuberculosis Reactivation Despite Correct Chemoprophylaxis and was Successfully Treated while on Anti-Tumour Necrosis Factor Therapy. Journal of Crohn's & colitis. 2016 May 23

PMID: 27215554

View Full Text